NCT03775265 2026-03-18
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
15 trialsNCT06211764 2026-03-17
SunRISe-5
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04166318 2026-03-02
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT01815359 2026-02-05
ICARuS
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06331299 2026-01-15
UTOPIA
UroGen Pharma Ltd.
Phase 3 Active not recruiting
NCT05902533 2025-12-18
REDEL
University of Cincinnati
Phase 2/3 Active not recruiting
NCT04216290 2025-11-12
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02701088 2025-09-22
CANAL-IMRT-01
Centre Francois Baclesse
Phase 2 Active not recruiting
NCT04046133 2025-08-05
CORINTH
Cardiff University
Phase 1 Active not recruiting
NCT02106572 2025-07-23
TIM
Abnoba Gmbh
Phase 3 Active not recruiting
NCT02299999 2025-01-15
SAFIR02_Breast
UNICANCER
Phase 2 Active not recruiting
NCT04241185 2024-11-25
MK-3475-992
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05243550 2024-11-04
ENVISION
UroGen Pharma Ltd.
Phase 3 Active not recruiting
NCT03018418 2024-09-19
Proton Therapy in Reducing Toxicity in Anal Cancer
University of Cincinnati
Phase 2 Active not recruiting
NCT06462001 2024-06-17
BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer
Nottingham University Hospitals NHS Trust
Phase 3 Active not recruiting